Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Zyrtec comparative onset of action claims "appear to be substantiated" -- FDA ad letter.

Executive Summary

PFIZER ZYRTEC ONSET OF ACTION COMPARISONS "APPEAR TO BE SUBSTANTIATED," FDA told the company in an April 28 letter from the Division of Drug Marketing, Advertising & Communications. The letter cites a pair of two-day trials comparing the Pfizer product to Schering-Plough's Claritin in terms of onset of antihistamine activity: a Journal of Allergy and Clinical Immunology study by Meltzer et al. and an unpublished study from a controlled environmental exposure unit.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel